ArticlemSphere2022
Interruption of Capsular Polysaccharide Biosynthesis Gene
Article in mSphere, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Stepwise phage resistance and collateral phage susceptibility inEmerging microbes & infections · 2026Article
- Phenotypic heterogeneity and genetic mechanisms of phage resistance in hypervirulent carbapenem-resistantVirulence · 2026Article
- Isolation, characterization, and therapeutic assessment of novel phage vB_LSKP32 targeting KL64-type carbapenem-resistant Klebsiella pneumoniae.Archives of virology · 2026Article
- Investigation of the therapeutic efficacy and resistance mechanisms of lytic phages targeting ST218 KL57 CR-hvKP.mSystems · 2026Article
- Bacteriophage Therapy AgainstMicroorganisms · 2026Review
- Article
- Characterization of NovelViruses · 2025Article
- Phages adapt to recognize an O-antigen polysaccharide site by mutating the "backup" tail protein ORF59, enabling reinfection of phage-resistantEmerging microbes & infections · 2025Article
- Infection and resistance mechanisms of phage vB_VpM-PP270 iniScience · 2025Article
- Investigating the phenotypic alterations associated with hypermucoviscous hypervirulent Klebsiella pneumoniae during phage resistance development.BMC microbiology · 2025Article
- Probiotic cell-free supernatant as effective antimicrobials against Klebsiella pneumoniae and reduce antibiotic resistance development.International microbiology : the official journal of the Spanish Society for Microbiology · 2025Article
- "Sichuanvirus", a novel bacteriophage viral genus, able to lyse carbapenem-resistant Klebsiella pneumoniae.BMC microbiology · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carbapenem-resistant Klebsiella pneumoniae (CRKP) is a major challenge for clinical management worldwide with limited antimicrobial options. Phages are considered an alternative option. Here, we isolated and identified a phage able to lyse ST11-K64 CRKP, the major type in China. This phage has a narrow host range, only lysing ST11-K64 CRKP, and inhibits the growth of host strains for 3 h forming large clear plaques (3.0 to 6.0 mm in diameter) with a surrounding halo. This phage exhibited excellent stability in different temperatures and pH and did not contain any virulence, lysogenic, antimicrobial resistance genes nor tRNA, meeting the criteria for phage therapy. Genomic analysis revealed that it represents a novel species of the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.